Search results
Author(s):
Jackson J Liang
,
David J Callans
Added:
3 years ago
As the population ages, the incidence of both AF and heart failure (HF) will continue to increase. By the year 2030, there will be an estimated >12 million patients with AF and >8 million patients with HF.1,2 A significant proportion of patients with HF have reduced (<50%) left ventricular ejection fraction (heart failure with reduced ejection fraction, HFrEF) and the coexistance of AF…
View more
Author(s):
Ivan Milinkovic
,
Marija Polovina
,
Andrew JS Coats
,
et al
Added:
1 year ago
Author(s):
Davide Stolfo
,
Gianfranco Sinagra
,
Gianluigi Savarese
Added:
1 year ago
Author(s):
Anjali Agarwalla
,
Jadry Gruen
,
Carli Peters
,
et al
Added:
2 years ago
HFA 2017: Targeting Heart Rate to Improve Mortality in Heart Failure With Reduced Ejection Fraction
Author(s):
John GF Cleland
Added:
6 years ago
Video
Author(s):
Giuseppe Rosano
,
Ilaria Spoletini
,
Cristiana Vitale
,
et al
Added:
3 years ago
Heart failure (HF) affects 1–2% of the population in developed countries and absorbs a significant amount of human and economic resources.1,2 HF is a complex syndrome characterised by a spectrum of symptoms and phenotypes: HF with preserved ejection fraction, HF with mid-range ejection fraction and HF with reduced ejection fraction (HFrEF).3 Differentiating patients according to left ventricular…
View more
Author(s):
Pieter Martens
Added:
2 years ago
Author(s):
Zachary L Cox
,
Shuktika Nandkeolyar
,
Andrew J Johnson
,
et al
Added:
1 year ago
Author(s):
James L Januzzi
Added:
1 year ago
HFSA 22 - Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction.
Questions:
1. What was the ideology behind PROVE-HF?
2. What is the mechanism of action behind…
View more